Match!

Current advances in tumor proteomics and candidate biomarkers for hepatic cancer

Published on Oct 1, 2009in Expert Review of Proteomics2.96
· DOI :10.1586/epr.09.72
Xin-Qing Peng1
Estimated H-index: 1
,
Fei Wang3
Estimated H-index: 3
(Tianjin Medical University)
+ 1 AuthorsWei-Ming Zhang1
Estimated H-index: 1
(Tianjin Medical University)
Cite
Abstract
Tumor proteomics apply proteomics techniques to tumor biological research, mainly by screening candidate biomarkers for early tumor diagnosis, prognosis and treatment. Hepatocellular carcinoma (HCC) is a type of malignant tumor with one of the highest death rates in the world. With the advent of the post-genomic age, tumor biological research developing the technology of proteomics has become a major focus of researchers. The discovery of novel candidate biomarkers is one of crucial problems for the early diagnosis of HCC. In general, there are three distinct types of candidate biomarkers for HCC based on different areas: biochemical biomarkers, antigenic biomarkers and epigenetic biomarkers. This review mainly discusses current advances in the problems and prospects of candidate biomarker for the early diagnosis of HCC, discovered by technologies of tumor proteomics.
  • References (50)
  • Citations (14)
Cite
References50
Newest
Published on Jun 1, 2009in Nature Methods28.47
Ruedi Aebersold146
Estimated H-index: 146
(UZH: University of Zurich)
A multilaboratory study attempts to dispel some of the notions of the irreproducibility of mass spectrometry–based proteomics by pinpointing where the methodological problems are and where challenges remain.
Published on Apr 1, 2009in Biochimica et Biophysica Acta3.79
Patrizia Bottoni21
Estimated H-index: 21
(UCSC: Catholic University of the Sacred Heart),
Bruno Giardina46
Estimated H-index: 46
(UCSC: Catholic University of the Sacred Heart)
+ 2 AuthorsRoberto Scatena23
Estimated H-index: 23
(UCSC: Catholic University of the Sacred Heart)
Drug induced cell differentiation represents a promising experimental model for proteomic analysis of cancer cells. In fact, by modulating and monitoring neoplastic cell differentiation it could be possible to identify cytodifferentiation related protein expression changes that can be subsequently utilized in vivo as potential cancer biomarkers. One main advantage of this approach is the significant reduction of biological variability normally observed in clinical biomarker research, with import...
Published on Oct 15, 2008in Journal of the National Cancer Institute10.21
Margaret Sullivan Pepe67
Estimated H-index: 67
(Fred Hutchinson Cancer Research Center),
Ziding Feng62
Estimated H-index: 62
(Fred Hutchinson Cancer Research Center)
+ 2 AuthorsJohn D. Potter121
Estimated H-index: 121
(Fred Hutchinson Cancer Research Center)
With the emergence of new molecular biotechnologies, the intensity of biomarker research has increased greatly, yet the scientific rigor of biomarker research lags far behind that of therapeutic research ( 1 – 3 ). In therapeutic research, the randomized placebocontrolled, blinded clinical trial takes the central role in pivotal evaluation of a new therapy. Standards for the conduct of such studies have been agreed upon internationally ( 4 ) ( www.ich.org ), and books and journals have been devo...
Published on Oct 15, 2008in Journal of the National Cancer Institute10.21
David F. Ransohoff60
Estimated H-index: 60
(UNC: University of North Carolina at Chapel Hill)
JNCI | Editorials 1419 The process to discover and develop molecular biomarkers for cancer diagnosis (or prognosis) is a work in progress and is evolving. “Discovery” research — searching for markers by use of highthroughput technology without an a priori hypothesis — has produced few useful biomarkers over the last 10 years despite numerous claims in research publications and news reports about “95% sensitivity and 95% specificity” or better. The degree of disconnect between claims and products...
Published on Oct 3, 2008in Journal of Proteome Research3.78
Raghothama Chaerkady33
Estimated H-index: 33
,
H. C. Harsha5
Estimated H-index: 5
(Johns Hopkins University)
+ 10 AuthorsO Sujay Singh1
Estimated H-index: 1
Hepatocellular carcinoma (HCC) is the fifth most common cancer worldwide. In this study, our objective was to identify differentially regulated proteins in HCC through a quantitative proteomic approach using iTRAQ. More than 600 proteins were quantitated of which 59 proteins were overexpressed and 92 proteins were underexpressed in HCC as compared to adjacent normal tissue. Several differentially expressed proteins were not implicated previously in HCC. A subset of these proteins (six each from ...
Published on Oct 1, 2008in Chinese journal of cancer3.62
Xiao-En Xu7
Estimated H-index: 7
(Fudan University),
Jiang Yh1
Estimated H-index: 1
,
Shi Q1
Estimated H-index: 1
The application of proteomics techniques to tumor biological research promoted the emergence of Tumor Proteomics.Its major goal is to screen biomarkers for tumor detection,diagnosis,prognosis,as well as tumor treatment using proteomics technologies,such as two dimensional gel electrophoresis(2-DE),stable isotope labeling of amino acid in cell culture(SILAC) and matrix assisted laser desorption/ionization(MALDI).Three stages of tumor proteomics study,including expression proteomics,post-translati...
Published on Oct 1, 2008in Molecular & Cellular Proteomics4.83
John M. Koomen38
Estimated H-index: 38
(USF: University of South Florida),
Eric B. Haura48
Estimated H-index: 48
(USF: University of South Florida)
+ 11 AuthorsLynne T. Hildreth1
Estimated H-index: 1
(USF: University of South Florida)
Cancer impacts each patient and family differently. Our current understanding of the disease is primarily limited to clinical hallmarks of cancer, but many specific molecular mechanisms remain elusive. Genetic markers can be used to determine predisposition to tumor development, but molecularly targeted treatment strategies that improve patient prognosis are not widely available for most cancers. Individualized care plans, also described as personalized medicine, still must be developed by under...
Hye-Jin Sung5
Estimated H-index: 5
,
Je-Yoel Cho28
Estimated H-index: 28
(KNU: Kyungpook National University)
Over a last decade, intense interest has been focused on bio-marker discovery and their clinical uses. This interest is accel-erated by the completion of human genome project and the progress of techniques in proteomics. Especially, cancer bio-marker discovery is eminent in this field due to its anticipated critical role in early diagnosis, therapy guidance, and prognosis monitoring of cancers. Among cancers, lung cancer, one of the top three major cancers, is the one showing the highest mortal-...
Tadashi Kondo1
Estimated H-index: 1
Novel cancer biomarkers are required to achieve early diagnosis and optimized therapy for individual patients. Cancer is a disease of the genome, and tumor tissues are a rich source of cancer biomarkers as they contain the functional translation of the genome, namely the proteome. Investigation of the tumor tissue proteome allows the identification of proteomic signatures corresponding to clinico-pathological parameters, and individual proteins in such signatures will be good biomarker candidate...
Published on Aug 19, 2008in PLOS Medicine
Amelie M. Lutz26
Estimated H-index: 26
(Stanford University),
Juergen K. Willmann13
Estimated H-index: 13
(Stanford University)
+ 2 AuthorsSanjiv S. Gambhir113
Estimated H-index: 113
(Stanford University)
Background Increasing efforts and financial resources are being invested in early cancer detection research. Blood assays detecting tumor biomarkers promise noninvasive and financially reasonable screening for early cancer with high potential of positive impact on patients' survival and quality of life. For novel tumor biomarkers, the actual tumor detection limits are usually unknown and there have been no studies exploring the tumor burden detection limits of blood tumor biomarkers using mathem...
Cited By14
Newest
Published on Jan 1, 2014in Cancer Cell23.92
Jie Li3
Estimated H-index: 3
(SJTU: Shanghai Jiao Tong University),
Ying Xu7
Estimated H-index: 7
(CAS: Chinese Academy of Sciences)
+ 10 AuthorsLi-Shun Wang14
Estimated H-index: 14
(SJTU: Shanghai Jiao Tong University)
Summary Cbx4 is a polycomb group protein that is also a SUMO E3 ligase, but its potential roles in tumorigenesis remain to be explored. Here, we report that Cbx4, but not other members of the Cbx family, enhances hypoxia-induced vascular endothelial growth factor (VEGF) expression and angiogenesis in hepatocellular carcinoma (HCC) cells through enhancing HIF-1α sumoylations at K391 and K477 in its two SUMO-interacting motifs-dependent mechanisms and increasing transcriptional activity of HIF-1. ...
Published on Aug 1, 2013in Analytica Chimica Acta5.26
Ran Liu10
Estimated H-index: 10
(SPU: Shenyang Pharmaceutical University),
Qing Li18
Estimated H-index: 18
(SPU: Shenyang Pharmaceutical University)
+ 3 AuthorsKaishun Bi28
Estimated H-index: 28
(SPU: Shenyang Pharmaceutical University)
Abstract To evaluate the potential relationship between cancer and polyamine metabolome, a UHPLC–MS/MS method has been developed and validated for simultaneous determination of polyamine precursors, polyamines, polyamine catabolite in human plasma and urine. Polyamine precursors including l -ornithine, lysine, l -arginine and S-adenosyl- l -methionine; polyamines including 1,3-diaminopropane, putrescine, cadaverine, spermidine, spermine, agmatine, N-acetylputrescine, N-acetylspermine and N-acety...
Published on Jan 1, 2013in Proteomics3.11
Stefan Balabanov24
Estimated H-index: 24
(Glas.: University of Glasgow),
Caroline A. Evans24
Estimated H-index: 24
(University of Manchester)
+ 5 AuthorsTessa L. Holyoake52
Estimated H-index: 52
(Glas.: University of Glasgow)
Chronic myeloid leukaemia (CML) arises in a haemopoietic stem cell and is driven by the Bcr-Abl oncoprotein. Abl kinase inhibitors (protein tyrosine kinase inhibitors) represent standard treatment for CML and induce remission in the majority of patients with early disease, however these drugs do not target leukaemic stem cells (LSCs) effectively, thus preventing cure. Previously, we identified the farnesyl transferase inhibitor BMS-214662 as a selective inducer of apoptosis in LSCs of CML patien...
Published on Oct 1, 2012in Proteomics3.11
Hem D. Shukla4
Estimated H-index: 4
(Johns Hopkins University),
Paulius Vaitiekunas3
Estimated H-index: 3
(Johns Hopkins University),
Robert J. Cotter72
Estimated H-index: 72
(JHUSOM: Johns Hopkins University School of Medicine)
Membrane proteomic analysis has been proven to be a promising tool for identifying new and specific biomarkers that can be used for prognosis and monitoring of various cancers. Membrane proteins are of great interest particularly those with functional domains exposed to the extracellular environment. Integral membrane proteins represent about one-third of the proteins encoded by the human genome and assume a variety of key biological functions, such as cell-to-cell communication, receptor-mediat...
Gisselle Gallego6
Estimated H-index: 6
(Johns Hopkins University),
John F. P. Bridges27
Estimated H-index: 27
(Johns Hopkins University)
+ 2 AuthorsLouis Niessen29
Estimated H-index: 29
(Johns Hopkins University)
There is a growing need for efficient procedures for identification of emerging technologies by horizon scanning systems. We demonstrate the value of best-worst scaling (BWS) in exploring clinicians' views on emerging technologies that will impact outcomes in hepatocellular carcinoma (HCC) in the next 5 to 10 years.
Published on Apr 6, 2012in Journal of Proteome Research3.78
Ramesh Ummanni5
Estimated H-index: 5
,
Frederico Barreto1
Estimated H-index: 1
+ 13 AuthorsGuido Sauter93
Estimated H-index: 93
The present study aimed to investigate the proteome profiling of surgically treated prostate cancers. Hereto, 2D-DIGE and mass spectrometry were performed for protein identification, and data validation for peroxiredoxin 3 and 4 (PRDX3 and PRDX4) was accomplished by reverse phase protein arrays (RPPA). The Formal Concept Analysis (FCA) method was applied to assess whether the TMPRSS2-ERG gene fusion could influence the degree of overexpression of PRDX3 and PRDX4 in prostate cancer. Lastly, we pe...
Published on Jan 1, 2012in International journal of hepatology
Franck Chiappini5
Estimated H-index: 5
(French Institute of Health and Medical Research)
Liver cancer is the fifth most common cancer in men and the seventh in women. During the past 20 years, the incidence of HCC has tripled while the 5-year survival rate has remained below 12%. The presence of circulating tumor cells (CTC) reflects the aggressiveness nature of a tumor. Many attempts have been made to develop assays that reliably detect and enumerate the CTC during the development of the HCC. In this case, the challenges are (1) there are few markers specific to the HCC (tumor cell...
Published on Jan 1, 2012in Central European Journal of Biology
Shilpa Bhatnagar2
Estimated H-index: 2
(Hamdard University),
Naveen Chaudhary3
Estimated H-index: 3
(Hamdard University)
+ 2 AuthorsS. K. Jain24
Estimated H-index: 24
(Hamdard University)
Lung cancer continues to represent a major public health concern with high morbidity and mortality worldwide. Early detection of lung cancer is problematic due to a lack of diagnostic markers with high sensitivity and specificity. To determine the differently expressed proteins in the serum of lung cancer and identify the function of such proteins, two-dimensional electrophoresis (2DE) and liquid chromatography mass spectrometry (LC-MS) were used to screen the serum of lung cancer model induced ...
Published on Jan 1, 2012
Natalia Olaya3
Estimated H-index: 3
,
Franck Chiappini10
Estimated H-index: 10
Hepatocellular carcinoma (HCC) is responsible for significant morbidity and mortality in cirrhosis and also accounts for between 85% and 90% of primary liver cancer (Caldwell & Park 2009; Hussain & El-Serag 2009; Tandon & Garcia-Tsao 2009). Most of HCC in the world occur in the setting of cirrhosis and over half-million of people develop liver cancer every year and an almost equal number die of it (Caldwell & Park 2009; Hussain & El-Serag 2009). Liver cancer prognosis is determined by factors re...
Published on Sep 1, 2011in Advanced Materials Research
Fei Wang3
Estimated H-index: 3
(Tianjin Medical University),
Yu Geng1
Estimated H-index: 1
+ 1 AuthorsXinGeng5
Estimated H-index: 5
(Tianjin Medical University)
To identify Zinc-alpha-2-glycoprotein (ZAG) expression in HCC for serum biomarker, by analyzing the serum proteome of the patients suffering from primary hepatocellular carcinoma (HCC), liver cirrhosis and healthy donors. The serum proteome of the patients from HCC, liver cirrhosis and healthy donors were separated and identified by two-dimensional electrophoresis. The differentially expressed proteins were analyzed by peptide mass fingerprint based on MALDI-TOF-MS and SWISS-PROT or BLAST nr dat...